Covered recipient · General Payments record
OLUSESAN OLUSEUN OLOTU
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2020–2024
$712.22
- Reported across 42 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $488.30 | 28 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $131.98 | 10 |
| ViiV Healthcare Company | $94.32 | 3 |
| Novo Nordisk AS | $76.51 | 4 |
| Acerta Pharma LLC | $50.42 | 3 |
| SHIELD THERAPEUTICS INC | $33.93 | 2 |
| Lilly USA, LLC | $32.76 | 2 |
| Amgen Inc. | $19.80 | 1 |
| GlaxoSmithKline, LLC. | $17.76 | 1 |
| Abbott Laboratories | $17.01 | 1 |
| PFIZER INC. | $13.81 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (28)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.01 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125031297 | CMS |
| ABBVIE INC. | $26.04 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152929 | CMS |
| ABBVIE INC. | $16.72 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152931 | CMS |
| ABBVIE INC. | $16.96 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152933 | CMS |
| ABBVIE INC. | $21.89 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152935 | CMS |
| ABBVIE INC. | $7.33 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152937 | CMS |
| ABBVIE INC. | $12.77 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152939 | CMS |
| ABBVIE INC. | $3.93 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152941 | CMS |
| ABBVIE INC. | $15.27 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152943 | CMS |
| ABBVIE INC. | $2.45 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152945 | CMS |
| ABBVIE INC. | $8.62 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105152947 | CMS |
| Amgen Inc. | $19.80 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117645173 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.09 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104323986 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.49 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104375225 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.84 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104318020 | CMS |
| GlaxoSmithKline, LLC. | $17.76 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116337737 | CMS |
| Lilly USA, LLC | $14.29 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135256061 | CMS |
| Lilly USA, LLC | $18.47 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135256066 | CMS |
| Novo Nordisk Inc | $21.05 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097441717 | CMS |
| Novo Nordisk Inc | $18.46 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097558861 | CMS |
| Novo Nordisk Inc | $20.74 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096891259 | CMS |
| Novo Nordisk Inc | $16.26 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096803645 | CMS |
| PFIZER INC. | $13.81 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132008150 | CMS |
| SHIELD THERAPEUTICS INC | $13.52 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150141378 | CMS |
| SHIELD THERAPEUTICS INC | $20.41 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150144136 | CMS |
| ViiV Healthcare Company | $42.21 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112728773 | CMS |
| ViiV Healthcare Company | $22.28 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112742757 | CMS |
| ViiV Healthcare Company | $29.83 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112727003 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.